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Abstract
Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Recent advances in
molecular diagnostics and immunotherapeutics have propelled the rapid development of novel treatment agents
across all cancer subtypes, including lung cancer. Additionally, more pharmaceutical therapies for lung cancer have
been approved by the US Food and Drug Administration in the last 5 years than in previous two decades. These
drugs have ushered in a new era of lung cancer managements that have promising efficacy and safety and also
provide treatment opportunities to patients who otherwise would have no conventional chemotherapy available. In
this review, we summarize recent advances in lung cancer therapeutics with a specific focus on first in-human or
early-phase I/II clinical trials. These drugs either offer better alternatives to drugs in their class or are a completely
new class of drugs with novel mechanisms of action. We have divided our discussion into targeted agents,
immunotherapies, and antibody drug conjugates for small cell lung cancer (SCLC) and non-small-cell lung cancer
(NSCLC). We briefly review the emerging agents and ongoing clinical studies. We have attempted to provide the
most current review on emerging therapeutic agents on horizon for lung cancer.
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Background
Lung cancer is the second most commonly diagnosed
cancer and is the leading cause of cancer-related death
in both men and women. Implementation of tobacco
control, low-dose spiral computed tomography screening
programs, and advances in multidisciplinary treatments
have resulted in the slow decline of both incidence and
mortality. However, 52–58% of lung cancer patients
present with advanced-stage disease, and a vast majority
of these patients do not survive despite treatment.
Similarly, the prognosis remains poor even in locally
advanced disease because of the high relapse rate and
early formation of micrometastases [1].
One of the most important therapeutic advances of
lung cancer treatment in the last decade was identifica-
tion of specific driver mutations and the development
of small molecular tyrosine kinase inhibitors (TKIs) [2].
In 2009, erlotinib was the first selective epidermal
growth factor receptor (EGFR) inhibitor approved by
the US Food and Drug Administration (FDA) [3]. This
was quickly followed by crizotinib, which was initially
developed as a MET (mesenchymal-to-epithelial transi-
tion/hepatocyte growth factor receptor) inhibitor and
was found to be highly active against small subset of
non-small-cell lung cancer (NSCLC) cases harboring
anaplastic lymphoma kinase (ALK) rearrangement [4].
These drugs promise around a 70% response rate; how-
ever, resistance development is almost universal, and
second/third generation TKIs are being developed to
overcome these issues. Novel targeted agents directed
against EGFR, ALK, ROS1, MET, RET, BRAF, and many
more are under investigation. Figure 1 provides sum-
mary of targets with specific focus on the drugs that
currently in early-phase clinical trials in lung cancer. In
addition to these drugs, next-generation sequencing
and cell-free DNA (cfDNA) technologies have provided
rapid and convenient tools for gene abnormality testing
and the development of targeted therapies [5]. Add-
itionally, personalized medicine has become part of
daily practice, and tailoring treatment for individual
patients is becoming a reality.
Immunotherapy in the form of checkpoint inhibitors
represents a landmark success in NSCLC treatment, and
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patients have experienced durable responses with good
tolerability. Pembrolizumab and nivolumab exert antitu-
mor activity by blocking programmed death receptor-1
(PD-1) on T lymphocytes. These drugs are currently
approved as second-line therapies for advanced NSCLC
based on pilot studies that show improved and durable
responses compared to docetaxel [6–8]. Most recently,
the FDA approved pembrolizumab for the treatment of
patients with metastatic NSCLC whose tumors express
strong PD-L1 in the first-line setting based on signifi-
cant improvement in progression-free survival (PFS)
and overall survival (OS) [9]. Trials are underway to
test using these agents as first-line therapies for pa-
tients with NSCLC either alone or in combination with
chemotherapy, TKIs, radiation, and other immunother-
apies [9–12]. For example, combinations of CTLA-4
and PD-1 inhibitors have been investigated in patients
with NSCLC and small cell lung cancer (SCLC). Pre-
liminary results from a phase I study demonstrated that
ipilimumab and nivolumab can be effectively and safely
combined as first-line treatment of advanced NSCLC
[10]. This combination is currently being tested in on-
going phase III study. Similarly, increased antitumor
activity was also seen in SCLC with this combination
[11]. Multiple studies are underway to investigate the
clinical activities of combined chemotherapy and
checkpoint inhibitors. Studies to investigate the roles of
checkpoint inhibitors in adjuvant and neoadjuvant
settings in early-stage lung cancers are ongoing as well.
These exciting developments have fuelled rapid pro-
gress in the field, and multiple molecules targeting
different aspects of host-tumor immune interactions
are currently being investigated. Figure 2 provides the
summary of ongoing strategies and efforts in immuno-
therapy of lung cancer.
In this review, we have discussed recently published
data on the first-in-human clinical trials and some of
the most promising drugs in pipeline. Literature was
searched for phase 1/2, first in human clinical trials in
lung cancer by using PubMed, Google scholar, and the
American Society of Clinical Oncology (ASCO) meeting
abstracts. Each study was individually reviewed and data
points have been summarized.
Targeted agents
EGFR inhibitors
EGFR is a member of the ErbB tyrosine kinase receptor
(TKR) family and is referred to as ErbB1 or HER1.
Gefitinib was first tested for EGFR-expressing NSCLC.
It targets the ATP cleft within EGFR, which is
Fig. 1 Molecular targets and inhibiting agents being studied in phase I/II trials as potential therapy for patients with lung cancer. Abbreviations:
AKT protein kinase B, ALK anaplastic lymphoma kinase, CREB3L2 cyclic AMP-responsive element-binding protein 3-like protein 2, EGFR epidermal
growth factor receptor, EML4 echinoderm microtubule-associated protein-like 4, ERK extracellular signal-regulated kinase, FGFR fibroblast growth
factor receptor, HGF hepatocyte growth factor, MCL1 myeloid leukemia cell differentiation protein, MEK mitogen-activated protein kinase, MET
mesenchymal-to-epithelial transition, mTOR mammalian target of rapamycin, PTEN phosphatase and tensin homologue, RAF rapidly accelerated
fibrosarcoma kinase, RET rearranged during transfection proto-oncogene
Dholaria et al. Journal of Hematology & Oncology  (2016) 9:138 Page 2 of 14
overexpressed in 40–80% of NSCLC cases. Later, Lynch
et al. demonstrated that only the tumors with somatic
mutations in tyrosine kinase domain of the EGFR gene
responded to gefitinib [13]. Testing for driver mutations
in newly diagnosed, advanced NSCLC cases has become
the standard of care. In patients who carry the targetable
driver mutation, a first-line treatment with targeted
agents is recommended over conventional chemother-
apy. These drugs are well tolerated and give predictable
objective response. A phase 2 trial in neo-adjuvant set-
tings has shown an improved response rate compared to
chemotherapy in EGFR+ NSCLC [14]. Driver mutations
in EGFR (exon 19 deletion or exon 21 L858R substitu-
tion) are found in 15–20% of all lung adenocarcinomas
(ACs) that account for the largest group of lung cancer
patients. Erlotinib, gefitinib, and afatinib are approved as
first-line treatments for targetable EGFR alterations. The
median progression-free survival (PFS) from these
agents is 9.2–13.1 months [15–17]. Dacomitinib is a
small molecule, irreversible inhibitor active against all
HER family of tyrosine kinases. In randomized trials, it
has comparable efficacy to erlotinib. The subgroup with
EGFR exon 19 deletion has better PFS with dacomitinib
compare to erlotinib (HR 0.585, P = 0.058) [18, 19]. A re-
cent phase 3 trial (NCT01040780) comparing icotinib
with gefitinib as the first-line EGFR TKI treatment
showed similar results in Chinese patients [20].
T790M mutant-selective EGFR TKIs
After the initial response to EGFR TKI, resistance devel-
opment through various mechanisms is inevitable. The
EGFR T790M mutation causes acquired resistance to
the first- and second-generation TKIs. T790M mutation-
selective third-generation EGFR TKIs (osimertinib,
rociletinib) have been developed with encouraging over-
all response rates up to 60% [21, 22]. Osimertinib was
approved in 2015 by the FDA for confirmed EGFR
T790M mutation-positive NSCLC. A first-line trial
(NCT02296125) is underway to compare osimertinib
vs erlotinib or gefitinib. This should give information
on ideal sequencing on these agents. ASP8273 and
olmutinib (BI1482694) are other third-generation
T790M-selective EGFR TKIs. Early-phase studies
(NCT02113813, NCT01588145) in T790M-positive
NSCLC showed an overall response rate (ORR) of 31%
and disease control rate (DCR) of 57% for ASP8273, as
well as a 61% ORR and 90% DCR for BI1482694. The
median PFS was 6.8 and 8.3 months, respectively [23, 24].
EGF816 is another agent that showed an ORR of 44% and
DCR of 91% in a phase 1 study (NCT02108964) [25].
Typical EGFR TKI-related adverse events were observed
with all three drugs.
CNS-penetrant EGFR TKIs
Central nervous system (CNS) metastasis is a common
site of disease progression in EGFR+ NSCLC, leading
to failure of the first-line TKIs. AZD3759 is a potent
CNS-penetrant EGFR TKI currently being evaluated
along with osimertinib in a phase 1 (BLOOM) study
(NCT02228369) in patients with progressive CNS me-
tastasis who have already had first-line treatment with
EGFR TKI. AZD3759 showed activity in 20 patients
with measurable brain metastasis evaluable for RECIST
assessment; 8 had tumor shrinkage in the brain, 3 had
confirmed partial response (PR), and 3 had uncon-
firmed PR [26]. In 12 patients taking osimertinib, 7 had
radiological PR, 2 had stable disease, and 3 were not
evaluable after 12 weeks [27].
Fig. 2 Multifaceted immunotherapy approaches to target cancer cell
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Epitinib is another small-molecule TKI being devel-
oped for its favorable CNS penetration. In a dose-
expansion phase, 12 patients with EGFR+ NSCLC and
CNS metastasis received epitinib. Among those 12 eva-
luable patients, 5 reached PR (all treatment naïve) and
showed dramatic shrinkage of brain lesions. The five
prior-TKI-treated patients had stable disease (SD) in the
brain [28] (NCT02590952).
ALK inhibitors
ALK fusion oncogene-associated NSCLC is a distinct
subset of lung cancer amenable to targeted therapy. ALK
rearrangement is found in 3–13% of NSCLC cases, with
a higher prevalence among younger patients, never or
light smokers, and adenocarcinoma with signet ring or
acinar histology [29]. Crizotinib is a multi-targeted TKI
that is active against ALK, ROS1, and MET [4]. It has
been approved as a first-line treatment for ALK+ or
ROS1+ NSCLC. Ceritinib and alectinib are second-
generation ALK TKIs approved for crizotinib-resistant
or intolerant cases [30–32]. Resistance development and
CNS progression are major issues, and the following
ALK TKIs are currently under investigation.
Brigatinib was given to 222 patients with crizotinib-
refractory, ALK+ NSCLC under a phase II study (ALTA,
NCT02094573). A PFS of 8.8 and 11.1 months was
noted among those receiving lower and higher doses of
brigatinib, respectively. An encouraging intracranial
ORR of 67% was seen in nine patients with measurable
CNS metastasis. Early onset pulmonary toxicity was seen
in 6% of the patients [33]. A phase III trial (NCT02737501)
against crizotinib in a front-line setting for ALK+ NSCLC
has been initiated.
Lorlatinib (PF-06463922) was tested in phase I/II study
(NCT01970865) of ALK+/ROS+ NSCLC. A majority of
the participants had a prior treatment with ≥2 ALK
TKIs. Among 41 evaluable patients, an ORR 46% and
median PFS of 11.4 months were seen. The intracranial
ORR was 44%, including a few complete responses (CRs)
[34]. Interestingly, the drug was active against diseases
caused by the ALK G1202R mutation which confers re-
sistance to ceritinib, alectinib, and brigatinib [35].
Ensartinib (X-396) is a novel ALK inhibitor with add-
itional activity against ROS1, MET, SLK, Axl, LTK, ABL,
and EPHA2. Partial responses were seen in 60% crizo-
tinib-naïve (30 patients) and 88% crizotinib-resistant pa-
tients (12 patients) (NCT01625234). CNS responses were
also observed in both groups [36]. A phase 3 study
(NCT02767804) comparing ensartinib and crizotinib in a
front-line setting is currently recruiting patients.
MET inhibitors
MET, a receptor tyrosine kinase after binding with
hepatocyte growth factor (HGF), activates the
phosphatidylinositol-3-kinase (PI3K) and mitogen-
activated protein kinases (MAPK) pathways. MET gene
amplification and exon-14-skipping mutations are
characteristic abnormalities causing increased MET
signaling activation. Isolated MET exon 14 mutation is
found in 3% of NSCLC; however, it is an acquired
EGFR TKI resistance pathway in 15–20% of EGFR
mutation-positive NSCLC cases [37, 38]. Crizotinib
has shown some activity in selected MET-amplified
and exon 14-skipping mutant NSCLC [39, 40]
(NCT00585195). Cabozantinib, a multi-targeted MET
inhibitor, was given to five patients with exon 14 muta-
tions and had a stable disease for 5 months [40]. Capmati-
nib (INC280) is a selective MET inhibitor. In a phase I
study (NCT01324479), relapsed NSCLC patients with
high cMET expression were given capmatinib. In sub-
group of patients with MET-amplified disease, the ORR
was 63%, and the median PFS was 7.4 months [41]. Glesa-
tinib (MGCD265) is another MET blocker currently being
studied in NSCLC (NCT00697632).
Combined MET + EGFR inhibitors
Acquired EGFR TKI resistance is mediated by MET up-
regulation in a subset of NSCLC patients. One strategy
to overcome this resistance is to combine a MET
inhibitor with an EGFR TKI. A combination of capma-
tinib and gefitinib was tested in a phase 2 study
(NCT01610336) in EGFR+ NSCLC patients after their
disease progressed while using gefitinib. EGFR T790M
NSCLCs were excluded and high cMET expression was
required. An ORR of 18%, an SD of 62%, and a DCR of
80% were observed in 65 evaluable patients. More re-
sponses were seen in tumors with MET amplifications
[42]. Tepotinib (MSC2156119J) with gefitinib was well
tolerated in a phase 1 study (NCT01982955). Eighteen
patients were treated, and five had a partial response
[43]. A similar trial (NCT01900652) with emibetuzu-
mab and an IgG4 anti-MET monoclonal antibody
(mAb) with erlotinib in MET-expressing NSCLC with
acquired erlotinib resistance showed some benefit in
high cMET-expressing tumors [44].
RET inhibitors
The RET proto-oncogene encodes a receptor tyrosine
kinase for members of the glial cell line-derived neuro-
trophic factor (GDNF) family. RET rearrangements are
found in 1–2% lung adenocarcinoma and are mutually
exclusive with mutations involving EGFR, ALK, or
KRAS. Vandetanib, sorafenib, sunitinib, lenvatinib, pona-
tinib, and cabozantinib are multi-targeted TKIs with
RET-blocking activity. They are currently approved for
other malignancies. In a phase 2 study with cabozanti-
nib, 38% PR was seen among 16 evaluable patients, and
there was a median PFS of 7 months [45].
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Vandetanib in advanced RET-rearranged NSCLC
showed an ORR 53%, a DCR 88%, and a median PFS of
4.7 months in 17 eligible patients. The CCDC6-RET
subtype had an ORR of 83% and a median PFS of
8.3 months [46] (UMIN000010095). In a phase 1 study
(NCT01582191), vandetanib was combined with evero-
limus (mTOR (mammalian target of rapamycin) inhibi-
tor) to prevent resistance development based on in
vitro studies. Among 13 stage IV NSCLC patients, PR
was achieved in five patients with RET fusion. Good
CNS activity was seen in three patients with intracra-
nial metastasis [47].
BRAF/MEK inhibitors
BRAF is a downstream signaling mediator of KRAS,
which activates the MAP kinase pathway. BRAF muta-
tions are found in 1–2% of NSCLC cases and are usu-
ally smoking related [48]. It is also described as one of
the resistance mechanisms associated with EGFR TKIs.
Vemurafenib and dabrafenib are currently approved for
BRAF V600E-positive malignant melanomas, but single-
agent activity in BRAF V600E- positive NSCLC is
limited. Dabrafenib had an ORR of 33% in platinum
refractory cases with a median duration of response of
9.6 months in single study [49] (NCT01336634).
Combination BRAF +MEK inhibitors
Sequential inhibition of BRAF and downstream MEK is
an active area of lung cancer research after encouraging
results were seen in melanoma patients. Dabrafenib
with trametinib (MEK inhibitor) was associated with
ORR of 63% in 57 evaluable patients and the DCR was
79% [50].
Combination MEK inhibitor and immunotherapy
MEK inhibition can result intratumoral T cell accumu-
lation and MHC-1 upregulation and synergizes with
anti-PD-L1 agent leading to tumor regression [51].
Cobimetinib is a selective MEK1 and MEK2 inhibitor.
In a phase 1b study (NCT01988896), cobimetinib with
atezolizumab (anti-PD-L1) was given to advanced solid
cancer patients. In colorectal cancer cohort (MSI-low),
ORR was 17% and responses were durable. Increased
PD-L1 and CD8 T lymphocyte infiltration was demon-
strated in serial biopsies [52]. Results on NSCLC cohort
are pending.
PI3K inhibitors
Phosphatidyl 3-kinase (PI3K) pathway is a central medi-
ator of cell survival signals. PI3CA mutations are found
in 4.4% of lung adenocarcinoma and 16% of squamous
cell cancer. PI3CA amplifications are found in up to 40%
of squamous cell lung cancer [53, 54]. PI3CA mutations
also promote resistance to EGFR TKIs. PQR309 is a
pan-PI3K, mTOR inhibitor. Its safety and maximum tol-
erated dose have been recently established in a phase 1
study (NCT02483858) with advance solid cancers. No
response data are available for NSCLC cohort [55].
HER3 inhibitors
Patritumab is a fully human anti-HER3 mAb. HER3 is a
member of the ErbB tyrosine kinase receptor family and
is activated by heregulin. Preclinical studies with EGFR+
NSCLC cell lines have shown that increased heregulin
level confers resistance to EGFR TKI. An initial phase 2
study (NCT01211483) failed to show the PFS benefit of
adding patritumab to erlotinib compared to a placebo.
However, the subgroup with increased soluble heregulin
showed increased PFS (HR 0.41 [95% CI 0.18–0.90], P =
0.02) with patritumab [56]. A phase 3 placebo-controlled
study (HER3-Lung, NCT02134015) in EGFR+ NSCLC
is ongoing.
Aurora A kinase inhibitors
Aurora A is a member of a family of mitotic serine/
threonine kinases which assist with cell proliferation.
Alisertib (MLN-8237) is an aurora kinase A inhibitor.
Based on in vitro synergism with EGFR TKIs, it was
tested in 18 patients with EGFR+ NSCLC. The combin-
ation was well tolerated; one patient had a PR, while five
other patients achieved SD [57]. Phase 2 recruitment is
ongoing (NCT01471964).
FGFR inhibitors
The fibroblast growth factor receptor (FGFR) binds to
members of the fibroblast growth factor family of pro-
teins and promotes cell proliferation. BGJ398 is a potent,
selective pan-FGFR (fibroblast growth factor receptor).
FGFR1 amplification is found in around 21% of squa-
mous NSCLC cases [58]. In a single phase 2 trial, 26
evaluable patients showed a PR of 15% and an SD if 35%
in dose >100 mg [59]. Dovitinib is another FGFR inhibi-
tor tested in squamous NSCLC. Among 26 patients, the
ORR was 11.5%, the DCR was 50%, and the median PFS
was 2.9 months [60].
PARP inhibitors
PARP (poly ADP ribose polymerase) plays an important
role in DNA repair. PARP inhibitors have synergistic ac-
tivity with platinum based chemotherapy (i.e., cisplatin)
[61]. In a phase 2 study, veliparib in combination with
carboplatin and paclitaxel was tested in first-line setting
for advanced NSCLC. The combination was well toler-
ated, and there was a trend toward favorable PFS (HR
0.72 [95% CI 0.45–1.15, P = 0.17]) and OS (HR 0.80
[95% CI 0.54–1.18, P = 0.27]) in combination arm [62].
A phase 2 combining veliparib with chemoradiation in
stage 3 NSCLC is recruiting (NCT02412371).
Dholaria et al. Journal of Hematology & Oncology  (2016) 9:138 Page 5 of 14
Immunotherapies
Immunotherapy has long been considered the holy grail
of Oncology. Different attempts have been made to har-
ness body’s immune system to eradicate malignancy.
Lung cancer has the second highest mutation burden
after melanoma, which increases its susceptibility to im-
munotherapy [63]. One of the key advantages of im-
munotherapy is the durability of responses. Where
resistance development is universal with chemotherapy
and targeted agents, memory function of the immune
system can lead to lasting remission. Check point inhibi-
tors target the PD1/PD-L1 axis to remove the inhibitory
signals on T lymphocytes to eradicate malignancy. Pem-
brolizumab and nivolumab are currently approved as
second-line therapies for both adenocarcinoma and
squamous cell carcinoma of lung. Atezolizumab is the
first anti-PD-L1 agent approved by the FDA for NSCLC
in second-line setting after encouraging results from
phase 3 OAK trial showing superior OS.(HR 0.73; P =
0.0003) [64]. A recent phase 3 study tested pembrolizu-
mab vs platinum doublet chemotherapy in first-line
NSCLC with at least 50% PD-L1expression in tumor
cells. Pembrolizumab was associated with better PFS
(10.3 vs 6 months) and response rate (44.8 vs 27.8%)
compared to chemotherapy. Estimated survival at
6 months was also better in patients treated with pem-
brolizumab (HR = 0.60, P = 0.005) [9]. This had led to
approval of pembrolizumab as first-line therapy in
NSCLC with >50% PD-L1 expression in tumor cells. A
combination of ipilimumab and nivolumab as first-line
treatment in advanced NSCLC is feasible, safe, and has
shown good ORR [10]. Durvalumab (anti-PD-L1) and
tremelimumab (anti-CTLA4) have been tested in phase
1b study and found to be safe with early evidence of
clinical activity in relapsed NSCLC [65]. As these agents
move quickly to treat early-stage lung cancers through
clinical studies, other agents that target different aspects
of the tumor-immune system milieu are being devel-
oped. Figure 2 demonstrates different strategies being
utilized to enhance tumor recognition and elimination
by the immune system [66].
OX40
OX40 (CD134) is a secondary costimulatory immune
checkpoint receptor expressed on activated T cells that
lead to expansion of effector and memory T cells after
binding with OX40L (CD252) on antigen presenting
cells. It is a part of tumor necrosis factor receptor
(TNFR) superfamily and works in conjunction with B7
family members, such as PD1 and CTLA-4. GSK3174998
is a humanized IgG1 agonistic anti-OX40 monoclonal
antibody (mAb) that promotes naïve CD4+ T- cells and
suppresses their differentiation into immunosuppres-
sive regulatory T cells (Treg) [67, 68]. ENGAGE-1
(NCT02528357) is a first-in-human study of GSK3174998
alone and in combination of pembrolizumab. Murine
studies have shown synergistic activity between PD-1
blockade and OX40 agonist mAb [69]. No dose-
limiting toxicity was found in the initial dose escalation
cohort alone and in combination with a 200-mg fixed
dose of pembrolizumab every 3 weeks. This study is
still recruiting patients.
MEDI6383 (NCT02221960) is another OX40 agonist
mAb currently being studied with durvalumab, an anti-
PD-1 antibody. Lirilumab/BMS-986015 (NCT01714739)
is anti-KIR mAb, which is a natural killer (NK)-cell check-
point inhibitor that is being evaluated with nivolumab.
Lymphocyte activation gene 3
Lymphocyte activation gene 3 (LAG-3, CD223) is an-
other checkpoint inhibitor on activated T lymphocytes
that inhibits immune function after binding with major
histocompatibility complex (MHC) II [70]. Urelumab is
an anti-LAG3 mAb currently being studied for NSCLC
in combination with anti-PD1 agents (NCT01968109,
NCT02460224).
T cell immunoglobulin and mucin-domain containing-3
T cell immunoglobulin and mucin-domain containing-3
(TIM-3) is Th1 (T helper-1)-specific regulator of macro-
phage responses. Recently, murine studies showed TIM-
3 upregulation in the tumor microenvironment in an
anti-PD1 resistant NSCLC model [71]. MBG453 and
TSR-022 are anti-TIM3 mAbs currently being studied in
two phase 1 trials (NCT02817633, NCT02608268).
B7-H3
B7-H3 is widely expressed among tumors and is associ-
ated with immune escape and metastasis. MGD009 is a
humanized B7-H3 and CD3 dual-affinity re-targeting
(DART) protein designed to engage T cells to B7-H3
expressing cells. Antitumor activity in multiple in vivo
models has been demonstrated. A phase 1 trial
(NCT02628535) in advanced B7-H3 expressing tumors,
including NSCLC, is recruiting patients [72]. Prior anti-
PD1 therapy is allowed.
MUC1
MUC1 is widely expressed in many malignancies, in-
cluding NSCLC. TG4010 is a modified vaccinia Ankara
expressing MUC1 and interleukin 2 (IL2). In a recent
phase 2b study, TG4010 or placebo were given with
chemotherapy as a first-line therapy for metastatic
NSCLC (mNSCLC) without EFGR mutations and MUC1
expression in minimum 50% of tumor cells. Significant
improvement in PFS (hazard ratio 0.74, 95% CI 0.55–
0.98, P = 0.019) was noted. The phase 3 component is
ongoing [73].
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GM.CD40L
GM.CD40L is an allogeneic tumor cell vaccine developed
from a human bystander cell line. Cells are transduced
with granulocyte-macrophage colony-stimulating factor
(GM-CSF) and CD40-ligand (CD40L) genes. In vivo, it
stimulates dendritic cell-mediated immune response.
CCL21 is a chemokine that helps with T cell responses. In
a phase 1/2 study (NCT01433172), GM.CD40L + CCL21
did not improve PFS, and the median OS was comparable
to single-agent chemotherapy in advanced adenoNSCLC.
A combination study with anti-PD1 is underway [74].
Antibody drug conjugates
Antibody drug conjugates (ADCs) are an important class
of biologics currently being investigated for range of ma-
lignancies. The chemotherapy molecule is attached to a
target-specific antibody for tumor-directed cytotoxicity
but sparing of normal tissue. Brentuximab vedotin
(CD30 directed) and transtuzumab emtansine (HER2
directed) are ADCs currently available for relapsed
Hodgkin lymphoma and metastatic HER2-positive breast
cancer, respectively. The following ADCs are currently
being studied in phase 1 trial for lung cancer.
Sacituzumab govitecan (IMMU-132)
Trop-2 is widely expressed among solid tumors. Sacitu-
zumab govitecan is made from a humanized anti-Trop-2
monoclonal antibody (hRS7) that is conjugated with the
active metabolite of irinotecan, SN-38. In a phase 1/2
study (NCT01631552), the single-agent sacituzumab
govitecan was given to patients with advanced epithelial
malignancies. In the NSCLC cohort, an objective re-
sponse of 31% and median PFS of 3.9 months was ob-
served. The SCLC cohort showed a similar response
rate, a median PFS of 4.6 months, and a median OS of
8.3 months [75, 76]. Diarrhea and neutropenia were
common adverse events. These are encouraging results
in platinum refractory patients. It has received the FDA
breakthrough therapy designation for triple-negative
breast cancer.
Rovalpituzumab tesirine (SC16LD6.5)
Rovalpituzumab tesirine also known as Rova-T is an
antibody (SC16) targeting delta-like protein 3 (DLL3)
and is linked to pyrrolobenzodiazepine (PBD). DLL3, an
inhibitory Notch ligand, is expressed in >80% of SCLCs.
The first biomarker directed trial for advanced SCLC
showed an objective response rate of 18% and a clinical
benefit rate of 68% as a second or third line of therapy
in evaluable patients. Interestingly, 27 patients with high
DLL3-tumor expression had a response rate of 44 and
45% in the second- and third-line settings, respectively
[77]. Thrombocytopenia, a skin rash, and serosal effu-
sions were dose-limiting toxicities. A phase 2 study
(TRINITY; NCT02674568) is recruiting patients with
DLL3-expressing SCLC.
Cancer stemness inhibitors
Cancer stem cells are highly resistant to traditional
therapies and cause disease relapse after initial response.
Napabucasin (BBI608) is a first-in-class cancer stemness
inhibitor that works through STAT3 pathway inhibition.
It has shown activity in combination with paclitaxel. In a
phase 2 study (NCT01325441), 27 heavily pretreated
NSCLC patients were given a combination of napabuca-
sin and weekly paclitaxel. Among 19 evaluable patients,
there was a PR of 16%, a DCR of 79%, and a median PFS
of 4 months [78].
Demcizumab (VS-6063) is a humanized IgG2 anti-DLL4
(delta-like ligand 4) antibody that inhibits tumor growth
by suppressing the Notch pathway. A phase 1b study
(NCT01189968) tested demcizumab with carboplatin and
pemetrexate as first-line therapies for lung adenocarcin-
oma. Results showed complete responses in one (3%) of
40 patients and partial responses in 19 (47%) patients [79].
A randomized, placebo-controlled phase 2 trial (DENALI)
(NCT02259582) has opened for first-line non-squamous
NSCLC. Another study (NCT01859741) of first-line
chemotherapy for SCLC is still recruiting patients.
Tarextumab (OMP-59R5) is a human anti-Notch 2/3
receptor mAb. In the phase 1b portion of the PINNA-
CLE study, tarextumab was given with etoposide/plat-
inum chemotherapy in the first-line extensive stage
SCLC. The combination was well tolerated. The RECIST
response was 77% with a median PFS and OS of 4.4 and
10.4 months, respectively, in 27 treated patients [80]. A
randomized study (NCT01859741) is ongoing.
Future directions
We discussed results of first-in-human phase I/II clinical
trials with novel agents in lung cancer in this article.
There are many new molecules which are currently
being studied for a variety of targets. Histone deacetylase
(HDAC) inhibitors and DNA hypomethylating agents
target epigenetics for tumor growth suppression. In
immunotherapy, new peptide vaccines targeting novel
tumor antigens, alternative checkpoint inhibitors, and
chimeric antigen receptor T cells (CAR-T) are being
developed for the patients who have failed or intolerant
to anti-PD1/anti-PD-L1 therapy. Novel small molecular
inhibitors directed to inhibit variety of signaling path-
ways are being developed to overcome resistance to cur-
rently available targeted therapies. Table 1 summarizes
currently open phase I/II clinical trials for lung cancer
patients with pending results. The information in this
table was collected from Clinicaltrils.gov (accessed on
September, 2016). It can serve as a guide for clinicians
who treat relapsed refractory lung cancer.
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Table 1 Currently open phase I/II clinical trials for lung cancer
Drug class Drug Mechanism of action Clinical trials (phase) Study design Disease
Tumor epigenetics Entinostat Histone deacetylase (HDAC) inhibitor NCT02437136 (1/2) Combination NSCLC
HBI-8000 NCT02718066 (1/2) Combination NSCLC
ACY 241 NCT02635061 (1) Combination NSCLC
Epacadostat NCT02298153 (1) Combination NSCLC
Mocentinostat NCT02805660 (1/2) Combination NSCLC
CC-486 DNA hypomethylation NCT02250326 (2) Combination NSCLC
Azacitidine NCT02009436 (1) Monotherapy NSCLC
RRX-001 DNA methylation, histone deacetylation,
and lysine demethylation
NCT02489903 (2) Monotherapy NSCLC
Tumor metabolism Ethaselen Thioredoxin reductase NCT02166242 (1) Monotherapy NSCLC
TAS-114 dUTPase NCT02855125 (2) Combination NSCLC
ADI-PEG 20 Pegylated arginine deiminase NCT02029690 (1) Combination NSCLC
CCT245737 Checkpoint kinase 1 NCT02797977 (1) Combination NSCLC/SCLC
LY2606368 NCT02860780 (1) Combination NSCLC/SCLC
CB-839 Glutaminase NCT02771626 (1/2) Combination NSCLC
Immunotherapy Cancer vaccines
CV301 Tumor peptide vaccine NCT02840994 (1/2) Combination NSCLC
TG4010 NCT02823990 (2) Combination NSCLC
Gemogenovatucel-T NCT02639234 (2) Combination NSCLC
CMB305 NCT02387125 (1) Monotherapy NSCLC
DC-CIK Dendritic cell vaccine NCT02688686 (1/2) Monotherapy NSCLC
DCVAC/LUCA NCT02470468 (1/2) Monotherapy NSCLC
AGS-003-LNG NCT02662634 (2) Monotherapy NSCLC
JNJ-64041757 Listeria vaccine NCT02592967 (1) Monotherapy NSCLC
ADXS11-001 NCT02531854 (2) Combination NSCLC
DSP-7888 WT1 vaccine NCT02498665 (1) Monotherapy NSCLC
S-588410 (HLA)-a*2402-restricted epitope peptides NCT02410369 (2) Monotherapy NSCLC
AD-MAGEA3 and MG1-MAGEA3 MAGE-A3-expressing maraba virus NCT02879760 (1/2) Monotherapy NSCLC
L-DOS47 Immunoconjugate NCT02340208 (1/2) Monotherapy NSCLC
NCT02309892 (1) Monotherapy NSCLC
DRibbles NCT01909752 (2) Monotherapy NSCLC
Checkpoint inhibitors
Enoblituzumab (MGA271) B7-H3 antibody NCT02475213 (1) Combination NSCLC
NCT01391143 (1) Monotherapy NSCLC
MGD009 NCT02628535 (1) Monotherapy NSCLC
CM-24 CEACAM1 antibody NCT02346955 (1) Combination NSCLC
Indoximod Indoleamine 2,3-dioxygenase
(IDO) inhibitor
NCT02460367 (1/2) Combination NSCLC
AMG 820 Colony-stimulating factor 1
receptor (CSF1R)
NCT02713529 (1/2) Combination NSCLC
PF-05082566 4-1BB agonist NCT02315066 (1) Combination NSCLC/SCLC
PBF-509 Adenosine A2a NCT02403193 (1/2) Combination NSCLC
CPI-444 NCT02655822 (1) Combination NSCLC
PF-04518600 Anti-OX40 mAb NCT02315066 (1) Combination NSCLC/SCLC
JNJ-61610588 Anti-VISTA NCT02671955 (1) Monotherapy NSCLC/SCLC
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Table 1 Currently open phase I/II clinical trials for lung cancer (Continued)
PDR001 Anti-PD1 NCT02460224 (1/2) Combination NSCLC/SCLC
CA-170 Oral PDL1/PDL2/VISTA inhibitor NCT02812875 (1) Monotherapy NSCLC/SCLC
Avelumab PD- L1 inhibitor NCT02584634 (2) Combination NSCLC
Varlilumab Anti-CR27 mAb NCT02335918 (1) Combination NSCLC
JNJ-64457107 Anti- CD40 NCT02829099 (1) Monotherapy NSCLC/SCLC
Modified T cell therapy
TIL Tumor infiltrating lymphocytes NCT02133196 (2) Monotherapy NSCLC
DC-CTL Combined dendritic cells-
cytotoxic t lymphocyte
NCT02766348 (2) Monotherapy NSCLC
NCT02886897 (1/2) Combination NSCLC
IMMUNICELL® Autologous γδ- T lymphocytes NCT02459067 (2/3) Monotherapy NSCLC
MAGE A10c796T Chimeric antigen receptor
T lymphocytes
NCT02592577 (1/2) Monotherapy NSCLC
NY-ESO-1c259T NCT02588612 (1/2) Monotherapy NSCLC
ANTI-MUC1 CAR T NCT02587689 (1/2) Monotherapy NSCLC
PD1 knockout cells Modified T cell therapy NCT02793856 (1) Monotherapy NSCLC
Targeted NK cells Modified NK cell therapy NCT02118415 (2) Monotherapy NSCLC
NCT02845856 (1/2) Combination NSCLC
WT1-TCRC4-T cells WT1 targeted t cells NCT02408016 (1/2) Monotherapy NSCLC
Cytokines
rSIFN-co Recombinant interferon NCT02387307 (1) Monotherapy NSCLC
ALT-803 IL- 15 agonist NCT02523469 (1/2) Combination NSCLC
AM0010 Pegylated IL-10 NCT02009449 (1) Monotherapy NSCLC
AAT-007 Prostaglandin E receptor subtype 4 NCT02538432 (2) Monotherapy NSCLC
Poly-ICL Toll-like receptor agonist NCT02661100 (1/2) Combination NSCLC/SCLC
VTX-2337 NCT02650635 (1) Monotherapy NSCLC
L19-IL2 Antibody cytokine fusion protein NCT02735850 (2) Combination NSCLC
CDX-1401 DEC-205/NY-eso-1 fusion protein NCT02661100 (1/2) Combination NSCLC/SCLC
Targeted therapy EGFR inhibitors
ABBV-221 EGFR NCT02365662 (1) Monotherapy NSCLC
AC0010MA EGFR T790M NCT02448251 (1/2) Monotherapy NSCLC
Tesevatinib EGFR (CNS penetrant) NCT02616393 (2) Monotherapy NSCLC
JNJ-61186372 EGFR/MET bispecific mAb NCT02609776 (1) Monotherapy NSCLC
AP32788 EGFR exon 20 NCT02716116 (1/2) Monotherapy NSCLC
MM-151 and MM-121 EGFR mAb NCT02538627 (1) Monotherapy NSCLC
TargomiRs EGFR ab bound mir-16 NCT02369198 (1) Monotherapy NSCLC
Multi-kinase inhibitors
Navitoclax Bcl-2, Bcl-x, Bcl-w NCT02520778 (1) Combination NSCLC
CT-707 ALK, FAK, Pyk2 NCT02695550 (1) Monotherapy NSCLC
Famitinib c-Kit, VEGFR2, PDGFR, VEGFR3,
FLT1, FLT3
NCT02356991 (2) Monotherapy NSCLC
NCT02364362 (1) Combination NSCLC
MGCD516 VEGFR, PDGFR, DDR2, TRK
and Eph families
NCT02219711 (1) Monotherapy NSCLC/SCLC
Pexidartinib Kit, FLT3, CAF1r NCT02452424 (1/2) Combination NSCLC
Anlotinib VEGF1/2/3, FGFR2 NCT02388919 (2/3) Monotherapy NSCLC
Entrectinib NTRK1/2/3, ROS1, ALK NCT02568267 (2) Monotherapy NSCLC
ASP2215 Axl, FLT3 NCT02495233 (1/2) Combination NSCLC/SCLC
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Table 1 Currently open phase I/II clinical trials for lung cancer (Continued)
PI3K/mTOR pathway inhibitors
MLN1117 PI3K NCT02393209 (1/2) Combination NSCLC
AZD8186 NCT01884285 (1) Monotherapy NSCLC
LY3023414 PI3K, mTOR NCT02443337 (2) Combination NSCLC
Other miscellaneous target inhibitors
LEE011 CDK 4/6 NCT02292550 (1/2) Combination NSCLC
Abemaciclib NCT02308020 (2) Monotherapy NSCLC
NCT02779751 (2) Monotherapy NSCLC
NCT02079636 (1) Combination NSCLC
INK128 TORC1/2 NCT02503722 (1) Combination NSCLC
Alisertib Aurora kinase inhibitor NCT01471964 (1/2) Combination NSCLC
Ibrutinib BTK NCT02321540 (1/2) Monotherapy NSCLC
TAK-659 Syk NCT02834247 (1) Combination NSCLC
Pyrotinib HER2 NCT02535507 (2) Monotherapy NSCLC
EphB4-HSA sEphB4 NCT02495896 (1) Combination NSCLC
Ficlatuzumab Hepatocyte growth factor (HGF) NCT02318368 (2) Combination NSCLC
AMG 479 IGFR-1 NCT01061788 (1) Combination NSCLC/SCLC
MM-121 HER3 NCT02387216 (2) Combination NSCLC
Defactinib Focal adhesion kinase (FAK) NCT02758587 (1/2) Combination NSCLC
JNJ-42756493 FGFR NCT02699606 (2) Monotherapy NSCLC
INCB054828 NCT02393248 (1/2) Monotherapy NSCLC/SCLC
LOXO-101 NTRK1/2/3 NCT02576431 (2) Monotherapy NSCLC/SCLC
RXDX-101 NCT02097810 (1) Monotherapy NSCLC/SCLC
Rh-endostatin NCT02375022 (2) Combination NSCLC
Cediranib NCT02498613 (2) Combination NSCLC/SCLC
GSK3052230 FGF ligand trap NCT01868022 (1) Combination NSCLC/SCLC
TRC105 Endoglin (CD105) NCT02429843 (1) Combination NSCLC
MEK162 MEK NCT01859026 (1) Combination NSCLC
PD-0325901 NCT02022982 (1/2) Combination NSCLC
Selumetinib RAS/RAF/MEK/ERK NCT01586624 (1) Combination NSCLC
Pacritnib JAK2 NCT02342353 (1/2) Monotherapy NSCLC
AT13387 Heat shock protein 90 NCT02535338 (1/2) Combination NSCLC
AUY922 NCT01922583 (2) Monotherapy NSCLC
NCT01854034 (2) Monotherapy NSCLC
Galunisertib TGFβ signaling NCT02423343(1/2) Combination NSCLC/SCLC
MSC2156119J MET NCT01982955(1/2) Combination NSCLC
Ralimetinib MAPK NCT02860780 (1) Combination NSCLC/SCLC
LTT462 NCT02711345 (1) Monotherapy NSCLC
PF-06671008 P-cadherin NCT02659631 (1) Monotherapy NSCLC/SCLC
BGB324 Axl NCT02424617 (1/2) Combination NSCLC
DNA repair VX790 ATR NCT02487095 (1/2) Combination SCLC
Veliparib PARP NCT01386385 (1/2) Combination NSCLC
Olaparib NCT02498613 (2) Combination NSCLC/SCLC
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Conclusions
Oncology is changing at a fast pace, and improved out-
comes are being observed in most human malignancies.
Until now, lung cancer has lagged behind, but novel
targeted agents and immunotherapies have shown prom-
ising results for this common and aggressive cancer. The
rapid development of novel agents targeting those mo-
lecular driver alterations in lung cancer will likely further
improve the clinical outcomes. The combination of
agents that target non-overlap pathways will likely pro-
vide additive or synergistic activities. Many studies are
ongoing to test new targets for immunotherapy such as
inhibitory molecules TIM-3, LAG-3, IDO (Indoleamine-
pyrrole 2,3-dioxygenase), BTLA (B- and T-lymphocyte
attenuator), adenosine, VISTA (V-domain immuno-
globulin containing suppressor of T cell activation), and
stimulatory molecules such as 4-1BB, OX40, CD40, and
CD27. A great number of clinical studies are underway
to test the clinical activities of various immunotherapy
combination strategies in different settings. However,
there are challenges to conquer. Treatment with target
agents inevitably leads to drug resistance. Understanding
the resistance mechanisms and developing novel agents
or strategies targeting the resistant tumors are largely
need. Although immunotherapy has shown durable
response in some patients, the majority of patients do
not benefit. Immunohistochemistry staining of PD-L1 on
tumor cells is extensively studied but still remains as
unperfect biomarker. Discovery of new biomarkers or
combination of biomarkers are required to guide the
selection of patients who most likely benefit from treat-
ment to avoid unnecessary costs and toxicities. Many
pre-clinical and clinical studies are ongoing to address
these needs.
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